Diamyd Medical (Sweden) Investor Sentiment

DMYD-B Stock  SEK 12.74  0.18  1.39%   
About 61% of Diamyd Medical's investor base is looking to short. The analysis of current outlook of investing in Diamyd Medical AB suggests that many traders are alarmed regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Quarterly Report I 2324 -January 24, 2024 at 0216 am EST - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medical S.A. Announces Interim Analysis of the Transformational Gene-Based Precision Medicine...
Google News at Macroaxis
over six months ago at news.google.com         
Serbian opposition figure to press on with hunger strike after health worsens - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Diamyd Medicals Precision Medicine patent for the prevention and treatment of autoimmune diabetes gr...
Google News at Macroaxis
over six months ago at news.google.com         
Bulletin from Annual General Meeting of Diamyd Medical AB - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
Annual Report 20222023 -November 29, 2023 at 0941 am EST - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical announces final outcome in the companys rights ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medicals vd om fretrdesemissionen - BioStock - Connecting Innovation and Capital
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical AB Reports Earnings Results for the Fourth Quarter ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical Founder Joins as Chairman -October 02, 2023 at ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
The Board of Directors in Diamyd Medical resolves on a rights issue ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Type 1 Diabetes Drugs Market Upcoming Opportunities with SWOT Analysis By 2030 - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical AB Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to...
Google News at Macroaxis
over a year ago at news.google.com         
By examining the market segmentation, sales volume, and share, the Type 1 Diabetes Drugs market size...
Google News at Macroaxis
over a year ago at news.google.com         
Results from Diamyd Antigen-Specific Immunotherapy Trial in LADA published in scientific journal - M...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Diamyd Medical that are available to investors today. That information is available publicly through Diamyd media outlets and privately through word of mouth or via Diamyd internal channels. However, regardless of the origin, that massive amount of Diamyd data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Diamyd Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Diamyd Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Diamyd Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Diamyd Medical alpha.

Diamyd Medical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Stocks Directory
Find actively traded stocks across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules